Sermorelin
Also known as: GHRH(1-29)NH2, hGRF(1-29)NH2, GRF 1-29, Geref, hGHRH(1-29)-NH2, SERM
Growth Hormone-Releasing Hormone (GHRH) analogue; growth hormone secretagogue
What it is
Sermorelin is a peptide people use to stimulate natural growth hormone release for aging-related GH decline, body composition, and recovery. It works by activating the same pituitary receptor as the natural hormone that triggers GH pulses. Previously FDA-approved; now only available through compounding; banned by WADA in sport.
The scientific side
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal active fragment of endogenous hypothalamic growth hormone-releasing hormone (GHRH). It binds to and activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, stimulating the secretion of endogenous growth hormone (GH), which in turn elevates circulating insulin-like growth factor-1 (IGF-1) levels. The peptide's plasma half-life is approximately 10–20 minutes in humans, limited primarily by renal ultrafiltration and enzymatic N-terminal degradation. Beyond pituitary actions, the GHRH receptor and its splice variants are expressed in multiple extrapituitary tissues including cancer cell lines, cardiac myocytes, retinal cells, corneal endothelium, and immune cells; activation or antagonism of this receptor modulates proliferation, apoptosis, inflammation, and redox signalling through pathways including cAMP/PKA, MAPK/ERK, JAK/STAT3, NF-κB, and HIF-1α.
Class: Growth Hormone-Releasing Hormone (GHRH) analogue; growth hormone secretagogue
At a glance
| What it is | A synthetic copy of the first 29 amino acids of growth hormone-releasing hormone (GHRH 1-29), the shortest piece that keeps full activity. |
|---|---|
| FDA status | Not currently approved. It was approved as Geref (1990 and 1997); the maker discontinued it in 2008, and FDA later found that was not for safety or effectiveness reasons. |
| Used for | Formerly growth hormone deficiency in children; now mostly anti-aging and sleep clinics, often compounded. |
| Human evidence | A 110-child trial behind its approval, plus small, short trials in older adults. |
| Half-life | About 10-20 minutes in humans, which is why it is usually injected at bedtime. |
| Banned in sport | Yes. WADA names it under S2.2.4 (growth hormone releasing factors), prohibited at all times. |
What is Sermorelin?
Sermorelin is a synthetic peptide matching the first 29 amino acids of human growth hormone-releasing hormone, the signal the brain sends to the pituitary to release growth hormone. It is the shortest fragment that keeps full activity, also written as GHRH(1-29)-NH2.
It is related to Tesamorelin, which uses the full 44-amino-acid sequence with a stabilizing group, and to Mod GRF 1-29 and CJC-1295, which modify the same 29-amino-acid sequence to make it last longer.
How does it work?
Sermorelin binds GHRH receptors on the pituitary, which releases the body's own growth hormone in a pulse. Because it works upstream, the response stays subject to the body's normal feedback controls, unlike injected growth hormone.
It is cleared within minutes, but the growth hormone response lasts longer: after IV doses in healthy men, growth hormone stayed elevated for about 3 hours. Bedtime injections aim to line this pulse up with the body's natural growth hormone release in early sleep.
Pharmacokinetics
| Half-life | About 10-20 minutes in humans |
|---|---|
| Metabolism | Broken down mainly by enzymes cleaving the N-terminus |
| Clearance | Mostly renal ultrafiltration |
| Route | Injection under the skin, usually at bedtime; intranasal bioavailability was only 3-5% |
Is it FDA-approved?
Not anymore. FDA approved sermorelin as Geref in 1990 to test pituitary growth hormone release, and in 1997 to treat children with idiopathic growth hormone deficiency. The maker, EMD Serono, discontinued both in 2008.
In 2013, FDA formally determined that Geref "was not withdrawn from sale for reasons of safety or effectiveness", which allows generic versions to be approved. None is currently marketed. FDA's list of compounding substances with significant safety risks does not name sermorelin.
- Formerly FDA-approved as: Geref (approved 1990; discontinued 2008)
- Why it was discontinued: Not withdrawn from sale for reasons of safety or effectiveness (FDA, 2013) Source
- WADA: S2.2.4 Growth hormone releasing factors (named among GHRH analogues; prohibited at all times)
History
Growth hormone-releasing hormone was isolated in 1982 from a human pancreatic tumor that had caused acromegaly. The first 29 amino acids turned out to carry its activity, and that fragment became sermorelin.
Serono developed it as Geref. A 110-child trial showed once-daily bedtime injections roughly doubled growth rates in children with growth hormone deficiency, and FDA approved the treatment form in 1997. With recombinant growth hormone dominating the market, Serono discontinued Geref in 2008. Sermorelin has since returned as a compounded "anti-aging" peptide.
Regulatory timeline
- December 28, 1990FDA approves Geref (sermorelin acetate) 0.05 mg to test the pituitary's ability to release growth hormone. Source
- September 26, 1997FDA approves Geref 0.5 mg and 1 mg vials to treat idiopathic growth hormone deficiency in children with growth failure. Source
- 2008EMD Serono notifies FDA that both Geref products are being discontinued (letters dated July 11 and December 2, 2008). Source
- March 4, 2013FDA determines Geref was not withdrawn from sale for reasons of safety or effectiveness. Source
- As of April 2026FDA's list of compounding substances with significant safety risks does not name sermorelin. Source
Side effects
In the trials behind its approval, sermorelin was well tolerated. Transient facial flushing and pain at the injection site were the most commonly reported adverse events. The 110-child trial found no adverse changes in blood chemistry or hormones, no change in fasting glucose and no excess IGF-1.
In older adults, a 6-week trial of 2 mg nightly reported no significant adverse effects. Long-term safety in adults using it for anti-aging has not been studied.
Common
- Facial flushing (transient)
- Pain at the injection site
Who should not use it
- No current label: the former Geref labeling is no longer in effect.
- Competitive athletes: prohibited at all times under WADA S2.2.4.
- Active cancer: it raises growth hormone and IGF-1, growth factors that approved GH-releasing drugs list as a contraindication.
- Pregnancy and breastfeeding: not studied in adults using it off-label.
Most commonly reported adverse events in the Geref trials, per the 1999 BioDrugs review; trials reported no serious drug-related events.
What does the research show?
In children with growth hormone deficiency, 30 micrograms/kg at bedtime raised height velocity from 4.1 to 8.0 cm per year at 6 months. Over time it worked less well than daily growth hormone injections.
In older men, 1 mg twice daily for 14 days restored growth hormone and IGF-1 toward young-adult levels. A single 2 mg nightly dose for 6 weeks raised night-time growth hormone but did not change IGF-1 or body composition; the authors concluded single nightly doses are less effective than multiple daily doses.
Two often-cited 1997 studies in older adults reported higher IGF-1 and lean mass, but they used [Nle27]GHRH(1-29), a modified version, not sermorelin itself.
Studied for
- Growth hormone deficiency in children (approved as Geref 1997-2008)
- Diagnosis of growth hormone deficiency (approved as Geref 1990-2008)
- Growth hormone and IGF-1 decline in older adults (small, short trials)
FAQ
Was Sermorelin ever FDA-approved?
Yes. As Geref, it was approved in 1990 for diagnosis and in 1997 to treat growth hormone deficiency in children. It was discontinued in 2008.
Was Geref pulled because it was unsafe?
No. In 2013 FDA determined Geref "was not withdrawn from sale for reasons of safety or effectiveness".
Sources: [6]
Is Sermorelin the same as growth hormone?
No. It signals the pituitary to release your own growth hormone, so the response stays under the body's normal feedback controls.
Sources: [1]
Why is Sermorelin taken at bedtime?
Its half-life is about 10-20 minutes, so each dose produces a short growth hormone pulse. Bedtime dosing lines that pulse up with the body's natural release in early sleep; the Geref pediatric trial dosed at bedtime.
Does Sermorelin raise IGF-1 in adults?
In one 14-day trial, 1 mg twice daily did. A single 2 mg nightly dose for 6 weeks did not.
Is Sermorelin on FDA's compounding risk list?
No. FDA's list of compounding substances with significant safety risks does not name sermorelin.
Sources: [7]
Is Sermorelin banned in sport?
Yes. The 2026 WADA Prohibited List names sermorelin under S2.2.4, prohibited at all times.
Sources: [13]
Citations
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999. PMID 18031173
- Esposito P, et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev 2003. PMID 14499707
- Wilton P, et al. Pharmacokinetics of GHRH(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl 1993. PMID 8329825
- Drugs@FDA: NDA 019863, Geref (sermorelin acetate) 0.05 mg/amp. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863
- Drugs@FDA: NDA 020443, Geref (sermorelin acetate) 0.5 and 1 mg/vial. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443
- FDA: Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. Federal Register, March 4, 2013. federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Guillemin R, et al. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982. PMID 6812220
- Thorner M; Geref International Study Group. Once daily subcutaneous GHRH therapy accelerates growth in GH-deficient children during the first year of therapy. J Clin Endocrinol Metab 1996. PMID 8772599
- Vittone J, et al. Effects of single nightly injections of GHRH (1-29) in healthy elderly men. Metabolism 1997. PMID 9005976
- Corpas E, et al. GHRH-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. J Clin Endocrinol Metab 1992. PMID 1379256
- Khorram O, et al. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997. PMID 9141536
- World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Sources
- Guillemin 1982. Guillemin R, et al. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982. pubmed.ncbi.nlm.nih.gov/6812220
- Prakash 1999. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999. pubmed.ncbi.nlm.nih.gov/18031173
- Esposito 2003. Esposito P, et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev 2003. pubmed.ncbi.nlm.nih.gov/14499707
- Wilton 1993. Wilton P, et al. Pharmacokinetics of GHRH(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl 1993. pubmed.ncbi.nlm.nih.gov/8329825
- Thorner 1996. Thorner M; Geref International Study Group. Once daily subcutaneous GHRH therapy accelerates growth in GH-deficient children during the first year of therapy. J Clin Endocrinol Metab 1996. pubmed.ncbi.nlm.nih.gov/8772599
- Corpas 1992. Corpas E, et al. GHRH-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. J Clin Endocrinol Metab 1992. pubmed.ncbi.nlm.nih.gov/1379256
- Vittone 1997. Vittone J, et al. Effects of single nightly injections of GHRH (1-29) in healthy elderly men. Metabolism 1997. pubmed.ncbi.nlm.nih.gov/9005976
- Khorram 1997. Khorram O, et al. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997. pubmed.ncbi.nlm.nih.gov/9141536
- Drugs@FDA (Geref 0.05 mg). Drugs@FDA: NDA 019863, Geref (sermorelin acetate) 0.05 mg/amp. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863
- Drugs@FDA (Geref 0.5/1 mg). Drugs@FDA: NDA 020443, Geref (sermorelin acetate) 0.5 and 1 mg/vial. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443
- Federal Register, 2013. FDA: Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. Federal Register, March 4, 2013. federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams
- FDA. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- WADA. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Administration & storage
- Administration
- Subcutaneous injection — human volunteer pharmacokinetic study (PMID: 26879649)Intravenous injection — diagnostic GH stimulation studies in humans (PMID: 105945209543138)Subcutaneous injection — animal (rat/pig) PEGylation pharmacodynamic studies (PMID: 14499707)
- Storage
- No storage conditions for sermorelin are described in the reviewed abstracts.
- Cautions
- Sermorelin's short plasma half-life (~10–20 min in humans) is caused by renal ultrafiltration and enzymatic N-terminal degradation; rapid elimination complicates pharmacodynamic management.,A case report associates long-term cyclical use of sermorelin/GHRP-6 combination therapy over approximately 20 years with anterior cervical osteophyte formation and dysphagia in a single patient; causality was not established.,Reported adverse effects associated with GH-axis modulating peptides in self-administration contexts include endocrine/metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention, myalgia/arthralgia, and injection-site reactions.,Products obtained from unregulated (gray-market) sources are frequently mislabeled or contaminated; falsified biopharmaceutical injectables including sermorelin have been seized in European anti-counterfeiting operations.,Potential for serious harm exists; rigorous human safety data are scarce for off-label and performance-enhancement uses.,Sterile technique is required for all injectable peptides to prevent injection-site infection and systemic contamination.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Prohibited. GHRH and its synthetic analogues (including sermorelin) are prohibited by the World Anti-Doping Agency (WADA). Multiple anti-doping detection methods have been developed and validated to WADA requirements.
Not stated in reviewed literature — requires manual verification
What it's studied for
- Growth hormone secretagogue — raising serum IGF-1 in hypogonadal men on testosterone therapy Human observational
- Retrospective review of 14 hypogonadal men prescribed 100 mcg each of GHRP-6, GHRP-2, and sermorelin (SERM) three times daily. Mean posttreatment IGF-1 rose from 159.5 to 239.0 ng/mL (p<0.0001) over a mean 134 days of treatment. Co-administration of aromatase inhibitors or tamoxifen attenuated IGF-1 increases. PMID 28830317 Sigalos JT et al. Am J Mens Health. 2017
- Diagnostic / physiological probe for GH secretion assessment Human RCT
- GHRH (100 mg, i.v.) with and without pyridostigmine was used to study GH dynamics in tall vs. short postpubertal men. No significant difference in GH response to GHRH was found between groups, and quantitative GH secretion did not appear to be an important determinant of final adult height in healthy individuals. PMID 10594520 Trainer PJ et al. Clin Endocrinol. 1999
- In healthy men, a specific GHRH antagonist (400 mcg/kg i.v.) blocked most of the GH response to GHRP-6 (1 mcg/kg i.v.), demonstrating that endogenous GHRH is necessary for most GH release elicited by GHRP-6. PMID 9543138 Pandya N et al. J Clin Endocrinol Metab. 1998
- Sports / athletic performance enhancement (off-label, unapproved use) Human observational
- Narrative review documenting sermorelin as one of the most commonly encountered GHRH analogues in online self-administration protocols for GH-IGF-1 axis modulation. Notes absence of regulatory approval for physique/performance indications and uncertainty about product composition, dosing, and stacking in unregulated su PMID 42395176 Dominikowski A et al. Front Endocrinol. 2026
- Review covering sermorelin as an unapproved peptide marketed to sports medicine patients. Notes favorable tissue repair and metabolic outcomes in animal models but scarcity of rigorous human safety data and potential for serious patient harm. PMID 41966639 Mendias CL & Awan TM. Sports Med. 2026
- Critical review classifying sermorelin as a GHRH analogue promoted for muscle growth, fat metabolism, and recovery. Notes most clinical evidence is from controlled therapeutic dosing, not supraphysiological or combined protocols used in bodybuilding. Highlights potential risks: cardiovascular strain, insulin resistance PMID 41880199 Coutinho LFD et al. J Sports Med Phys Fitness. 2026
- Musculoskeletal injury recovery / orthopaedic adjunct (proposed, largely preclinical) Animal studies only
- Review noting that growth hormone secretagogues including sermorelin activate IGF-1 signalling and satellite cell repair. Concludes preclinical studies are promising but there is a current lack of clinical trials for orthopaedic applications. PMID 41490200 Rahman OF et al. J Am Acad Orthop Surg Glob Res Rev. 2026
- Adult-onset growth hormone insufficiency management Human observational
- Editorial discussing sermorelin as an approach to management of adult-onset growth hormone insufficiency (no abstract text provided; limited extractable data). PMID 18046908 Walker RF. Clin Interv Aging. 2006
- Cardioprotection / heart failure (preclinical — GHRH receptor agonist pathway, studied with synthetic GHRH agonists, not sermorelin itself) Animal studies only
- Sermorelin is listed as a named GHRH receptor agonist in the MeSH of this study investigating the GHRHR-HIF-1α axis in HFpEF mouse models and human iPSC-derived cardiomyocytes. The experimental agent used was MR-356, not sermorelin. Study demonstrates the GHRHR-HIF-1α axis is required for beneficial cardiac effects of PMID 42465868 Kanashiro-Takeuchi RM et al. Am J Physiol Heart Circ Physiol. 2026
- GHRH agonists (JI-38, MR-356, MR-409) reduced MI size, increased cardiac c-kit+ cells, mitotic divisions, and vascular density in infarcted rats. Sermorelin is listed in MeSH context as a GHRH reference compound; the active agents studied were synthetic agonists, not sermorelin itself. PMID 25797248 Kanashiro-Takeuchi RM et al. Oncotarget. 2015
- Diabetic retinopathy protection (preclinical, GHRH agonist pathway) Animal studies only
- Streptozotocin-diabetic rats treated with GHRH agonist MR-409 (15 µg/kg) showed retinal neuroprotection, antioxidant and anti-inflammatory effects, and reduced vascular permeability. Sermorelin appears in MeSH as a GHRH reference; the active agent studied was MR-409. PMID 29180438 Thounaojam MC et al. PNAS. 2017
- Type 1 diabetes / beta-cell protection (preclinical, GHRH agonist pathway) Animal studies only
- GHRH agonist MR-409 protected beta-cells from streptozotocin-induced T1D in mice via cAMP/PKA/CREB/IRS2 signalling. Sermorelin appears in MeSH as a GHRH reference compound; the active agent studied was MR-409. PMID 37307472 Louzada RA et al. PNAS. 2023
- Doping control detection target (anti-doping / forensic analytical context) Human observational
- Nano-LC-Q/Orbitrap MS method validated to WADA requirements for detection of sermorelin/CJC-1293, tesamorelin, and CJC-1295 in urine; achieved LODs ≤0.5 ng/mL and LOIs 0.5–0.75 ng/mL. PMID 41138283 Uçaktürk E & Nemutlu E. J Pharm Biomed Anal. 2026
- LC-MS/MS method developed for detection of sermorelin and metabolites in urine; LOD generally ≤1 ng/mL. Nineteen in vitro metabolites of GHRH analogues including sermorelin were identified and used as reference materials. PMID 34665524 Memdouh S et al. Drug Test Anal. 2021
- Immunoaffinity purification with nano-UHPLC-HRMS method detected sermorelin (Geref), CJC-1293, CJC-1295, and tesamorelin in human plasma; LLOQ <50 pg/mL. A sermorelin metabolite (GHRH3-29) was detected in human plasma after s.c. injection to a healthy male volunteer. PMID 26879649 Knoop A et al. Anal Bioanal Chem. 2016
Safety signals
- Long-term self-administration of sermorelin/GHRP-6 combination (approximately 20 years) associated in a single case report with symptomatic anterior cervical osteophyte formation and dysphagia in a 62-year-old male; causality unproven but hypothesis raised regarding chronic GH axis stimulation contributing to osteophyte growth in setting of prior cervical trauma PMID 42465868
- Off-label GH-axis peptide use (including sermorelin) associated with reported adverse effects spanning endocrine/metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions PMID 42395176
- Potential cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability reported in association with peptide use (including GHRH analogues such as sermorelin) in bodybuilding contexts PMID 41880199
- Products sourced from unregulated gray markets may be mislabeled or contaminated, posing direct patient safety risks; sermorelin has been identified among seized falsified biopharmaceutical injectables in Europe PMID 26456392
- Rigorous human safety data for sermorelin use in sports/performance contexts are scarce; potential for serious harm acknowledged PMID 41966639
- Inhibition of estrogen production or estrogen receptor blockade (co-administration of aromatase inhibitors or tamoxifen) during GHRP/sermorelin therapy resulted in smaller increases in IGF-1 levels, suggesting hormonal interactions that may affect therapeutic outcomes PMID 28830317
Contraindications
- No absolute contraindications are explicitly stated in the reviewed abstracts. The reviewed literature does not provide formal contraindication data for sermorelin in human therapeutic use. PMID 41966639
Protocol
200 mcg subcutaneous injection, daily, before bed. Cycle: 8-12 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Not explicitly stated in abstract (prescribed combination therapy) | 100 mcg of sermorelin (SERM) three times daily (combined with 100 mcg GHRP-6 and 100 mcg GHRP-2 three times daily) | Mean 134 days (range not fully specified) | human | Research PMID 28830317 |
| intravenous | 100 mg GHRH intravenously (diagnostic bolus) | Single administration | human | Research PMID 10594520 |
| intravenous | 1 mcg/kg GHRP-6 i.v. bolus (with or without 400 mcg/kg i.v. GHRH antagonist); sermorelin used as GHRH reference | Single administration | human | Research PMID 9543138 |
| subcutaneous | Dose not specified (pharmacokinetic/metabolite study after s.c. injection to one healthy male volunteer) | Single administration; samples collected at 2, 4, 8 h post-dose | human | Research PMID 26879649 |
| subcutaneous injection | 200-300 mcg | daily, before bed · 3-6 months | adults 30+ using for anti-aging / longevity, GH optimization | [Community] |
| subcutaneous injection | 300 mcg | daily, before bed · 6 months | men 40+ on TRT seeking GH axis support without exogenous HGH | [Community] |
| subcutaneous injection | 200 mcg | daily, before bed · 3 months minimum | beginners / newcomers to GH secretagogues | [Community] |
| subcutaneous injection | 500 mcg | daily, before bed · 3-6 months | experienced biohackers seeking stronger GH pulse amplitude | [Community] |
| subcutaneous injection | 100 mcg | daily, before bed · 3-6 months | older adults (60+) or those with pituitary sensitivity concerns | [Community] |
| subcutaneous injection | 200-300 mcg | daily, before bed · 3-6 months | athletes and fitness-focused adults targeting sleep quality and recovery | [Community] |
| subcutaneous injection | 200 mcg | daily, before bed · 8-12 weeks | healthy adults using Sermorelin + GHRP-2 stack | [Community] |
| subcutaneous injection | 200 mcg | daily, before bed · 8-12 weeks | healthy adults using Sermorelin + GHRP-6 stack | [Community] |
| subcutaneous injection | 200 mcg | daily, before bed · 8-12 weeks | body recomposition users combining Sermorelin with Ipamorelin | [Community] |
| subcutaneous injection | 300 mcg | 5 days on / 2 days off (weekdays) · 3-6 months | biohackers preferring cycling protocols to limit pituitary desensitization | [Community] |
| subcutaneous injection | 500 mcg | twice daily (morning fasted + pre-bed) · 8-12 weeks | advanced biohackers seeking maximal GH output, often stacked with a GHRP | [Community] |
All studies (17)
- PMID 9543138 Human RCT
Diagnostic / physiological probe for GH secretion assessment - PMID 10594520 Human RCT
Diagnostic / physiological probe for GH secretion assessment - PMID 18046908 Human observational
Adult-onset growth hormone insufficiency management - PMID 26879649 Human observational
Doping control detection target (anti-doping / forensic analytical context) - PMID 28830317 Human observational
Growth hormone secretagogue — raising serum IGF-1 in hypogonadal men on testosterone therapy - PMID 34665524 Human observational
Doping control detection target (anti-doping / forensic analytical context) - PMID 41138283 Human observational
Doping control detection target (anti-doping / forensic analytical context) - PMID 41880199 Human observational
Sports / athletic performance enhancement (off-label, unapproved use) - PMID 41966639 Human observational
Sports / athletic performance enhancement (off-label, unapproved use) - PMID 42395176 Human observational
Sports / athletic performance enhancement (off-label, unapproved use) - PMID 14499707
Not specified for sermorelin alone; PEGylated GRF conjugates tested i.v. and s.c. in rats and pigs intravenous, subcutaneous (animal) - PMID 25797248 Animal studies only
Cardioprotection / heart failure (preclinical — GHRH receptor agonist pathway, studied with syntheti - PMID 26456392
Products sourced from unregulated gray markets may be mislabeled or contaminated, posing direct patient safety risks; sermorelin has been identified among seize - PMID 29180438 Animal studies only
Diabetic retinopathy protection (preclinical, GHRH agonist pathway) - PMID 37307472 Animal studies only
Type 1 diabetes / beta-cell protection (preclinical, GHRH agonist pathway) - PMID 41490200 Animal studies only
Musculoskeletal injury recovery / orthopaedic adjunct (proposed, largely preclinical) - PMID 42465868 Animal studies only
Cardioprotection / heart failure (preclinical — GHRH receptor agonist pathway, studied with syntheti
Frequently asked
What does sermorelin do and how does it work?
Sermorelin is a synthetic 29-amino-acid peptide that mimics the first 29 amino acids of the body's own growth hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary gland, stimulating the release of endogenous growth hormone, which in turn raises IGF-1 levels. Its plasma half-life in humans is approximately 10–20 minutes due to rapid enzymatic and renal clearance.
What dose of sermorelin should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: one retrospective study in hypogonadal men used 100 mcg of sermorelin combined with 100 mcg GHRP-6 and 100 mcg GHRP-2 three times daily. In diagnostic settings, GHRH has been administered as a single 100 mg i.v. bolus. These doses were used in specific research contexts and should not be extrapolated to individual self-administration.
Is sermorelin legal or banned?
GHRH and its synthetic analogues, including sermorelin, are prohibited by the World Anti-Doping Agency (WADA) in competitive sport. Multiple validated detection methods exist for sermorelin in urine and plasma to enforce this prohibition. Its prescription regulatory status in specific countries is not explicitly stated in the reviewed literature — please consult a licensed healthcare provider or the relevant regulatory authority for your jurisdiction.
Can sermorelin be used for muscle building or athletic performance?
Sermorelin is used off-label and without regulatory approval for physique and performance-related purposes. Reviewed literature notes its use in these contexts but concludes that clinical evidence is limited, most published studies examine therapeutic applications under controlled dosing, and potential risks include cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability. Sermorelin is prohibited by WADA in competitive sport. Products obtained outside licensed channels may be mislabeled or contaminated.
What are the side effects or safety risks of sermorelin?
Based on reviewed literature, reported concerns associated with sermorelin and related GH-axis peptides include: endocrine/metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention, myalgia/arthralgia, and injection-site reactions. One case report associates approximately 20 years of sermorelin/GHRP-6 combination use with cervical osteophyte formation and dysphagia, though causality was not established. Unregulated supply carries contamination and mislabeling risks. Rigorous human safety data for off-label performance use are scarce.
Can I combine sermorelin with other peptides like ipamorelin, CJC-1295, or GHRP-6?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: one retrospective study used a combination of sermorelin with GHRP-6 and GHRP-2 (each 100 mcg three times daily) and observed IGF-1 increases. A mechanistic study showed GHRP-6 requires endogenous GHRH signalling for maximal GH stimulation, which is the pharmacological rationale for combinations. Risks associated with combined peptide protocols, including unregulated stacking, are not well characterised in the literature.
Where can I buy sermorelin?
I don't recommend vendors or sources. Please consult a licensed provider.
Will sermorelin show up on a drug test?
Yes. Multiple validated analytical methods have been developed specifically to detect sermorelin (and its metabolites) in urine and plasma for WADA anti-doping purposes. Achieved limits of detection in urine are ≤0.5–1 ng/mL. In a pharmacokinetic study, a sermorelin metabolite (GHRH3-29) was detected in human plasma at 4–8 hours after a single subcutaneous dose.
Is sermorelin safe for long-term use?
Long-term safety data for sermorelin in healthy adults are not established in the reviewed literature. One case report described a 62-year-old man with approximately 20 years of cyclical sermorelin/GHRP-6 combination use who developed symptomatic cervical osteophyte formation, though causality was not proven. Reviewed literature consistently notes that rigorous human safety data are scarce and that long-term risks remain poorly defined. Please speak with a licensed healthcare provider.
Does sermorelin help with fat loss?
I don't have reliable study data on sermorelin specifically for fat loss in the reviewed abstracts. One retrospective study in hypogonadal men prescribed sermorelin combined with GHRPs noted that participants were seeking lean body mass and fat loss, and IGF-1 levels increased significantly, but body composition outcomes were not reported. I won't guess — please consult a licensed provider or peer-reviewed literature directly.